AR-cPLA2

Rong Wan1, Jun Zhou2, Rongchen Mao3

  • 1Department of Pharmacology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, China; Jiangxi Key Laboratory of Molecular Medicine, the Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.

概括

糖尿病中的甲基醇 (MGO) 通过降低受体 (AR) 的调节和增加氧化应激,导致冠状动脉微血管功能障碍 (CMD). AR激活可以防止这种损伤,这可能解释了糖尿病心脏病中的性别差异.